altRX vs Hers
altRX costs $50 less a month, and both sell semaglutide and tirzepatide.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Hers
Best for: coverage in all 50 states, which most sellers will not confirm
Visit Hers →If you are choosing between altRX and Hers, the first difference is cost: altRX is $50 a month cheaper at the entry price. Both prescribe semaglutide and tirzepatide, so moving from one to the other would not change your drug. Hers leads our six-part score, 7.0 to 6.7. One of the two has an FDA warning letter on record, covered below.
altRX vs Hers price
altRX is the cheaper way in: $149 a month against $199 a month at Hers. That is $50 less each month (25% lower), or about $600 over a year of treatment.
Drug by drug: Semaglutide is cheaper at altRX ($149 a month vs $199 a month); tirzepatide is cheaper at altRX ($249 a month vs $299 a month).
Medications and formats
Both sell semaglutide and tirzepatide.
On format they match: each offers compounded injections and brand-name pens.
Where each one treats patients
altRX does not publish where it ships, and Hers lists 50 states.
Pricing
altRX
Hers
Brand Zepbound from $299/mo medication-only; requires Hers Weight Loss Membership ($149/mo)
What each price covers
Both prices cover the medication itself.
altRX's price also covers the clinician visit and shipping, which Hers does not claim.
altRX is silent on lab work and coaching.
Hers is silent on shipping and lab work.
altRX
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Hers
Covered by the monthly price
Medication
In the price
Clinician visits
Charged on top
Shipping
Not stated
Lab work
Not stated
Coaching
Charged on top
Where each one scores higher
Overall, Hers scores 7.0 and altRX 6.7 out of 10.
altRX is stronger on value (5.0 vs 3.0) and support (7.0 vs 3.0).
Hers is stronger on trust & safety (8.5 vs 3.5) and accessibility (10.0 vs 5.0).
Effectiveness and user experience are within half a point.
altRX
6.7/10
Hers
7.0/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
The FDA sent altRX a warning letter dated June 8, 2026 (letter 728236), and it is still open.
Hers has no FDA warning letter on record with us.
Features & Coverage
| Feature | altRX | Hers |
|---|---|---|
| Starting Price | ✓$149/mo | $199/mo |
| Features | ✓8 features | 2 features |
| States Available | Not disclosed | 50 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warning Letters | 1 letter | ✓None |
About altRX
Compounded plans open at $149 for semaglutide and $249 for tirzepatide. Branded medication runs $1,149-$1,579, a figure that already contains the consult and the shipping. Every one of the four FDA-approved brands is stocked, Mounjaro, Ozempic, Wegovy and Zepbound, which no other entry in our directory matches. altRX works in both modalities, holds LegitScript certification, and prints the FDA compounded-medication disclaimer.
Read our full altRX review →About Hers
Hers is the women-focused telehealth brand from Hims and Hers. It sells compounded semaglutide on a 6-month plan.
Read our full Hers review →Pros & Cons
altRX
What we like
- Tirzepatide costs $1249 a month, close to the $1249 median for brand-name tirzepatide across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication, clinician visits and shipping
Watch-outs
- Semaglutide costs $1149 a month, 16% above the $990 median for brand-name semaglutide across the sellers we compare
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- The FDA has issued altRX a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Hers
What we like
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication
- Serves all 50 states
- We found no FDA warning letters issued to Hers
Watch-outs
- Not included in the monthly price: clinician visits, coaching
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
Hers wins this one, 7.0 to 6.7, above all for coverage in all 50 states, which most sellers will not confirm. altRX undercuts it by $50 a month, so if the monthly bill is what decides it, altRX is the pick. altRX fits better if semaglutide from $1149/month is your priority.
Choose altRX if…
You want semaglutide from $1149/month and an opening price near $149 a month.
Choose Hers if…
You want coverage in all 50 states, which most sellers will not confirm and an opening price near $199 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo
Get started →Found
Tirzepatide at $169/month, 37% below the typical price
From $149/mo
Get started →Breeze Meds
Knowing which pharmacy fills the vial: it names Belmar Pharmacy
From $199/mo
Get started →altRX vs Hers: FAQ
Close alternatives to altRX and Hers
- altRX vs Gala
- altRX vs Sprout Health
- altRX vs Aquivia Health
- altRX vs Vytora Health
- Hers vs Hims
- Hers vs Noom
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.